Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.
Plenary 2 rieb pain and addiction
1. Managing Pain in Patients
With or at Risk for Substance
Use Disorders
Launette Rieb MSc, MD, CCFP, CCSAM, FCFP, dip. ABAM
Clinical Associate Professor, Dept. of Family Medicine, UBC
Director, St. Paul’s Hospital Goldcorp Addiction Medicine Fellowship
FME March 7-8, 2014, Vancouver, BC
2. Faculty/Presenter Disclosure
Faculty: Launette Rieb
Relationship with commercial interests:
Grants/research support:
UBC Clinical Scholar’s Program
UBC Special Populations Grants
Speaker’s bureau honoraria:
FME (Oregon College of Physicians), CPSBC, UBC-
CPD, various health authorities, Qatar Olympic Bid
Committee, WorkSafeBC, SPH-CME
Consulting fees: OrionHealth, Orchard Recovery
Providence Health (St. Paul’s Hospital)
3. Learning Objectives
1. Gain an appreciation of the overlap between
chronic pain & addictive disorders and how
effective management is similar
1. Differentiate pain disorders, substance use
disorders, physiologic dependence, and pseudo-
addiction
2. Develop insight to caregiver suffering in working
with people in pain and/or addicted
9. Dopamine D2 Receptors are Lower in
Addiction
control addicted
Cocaine
Heroin
Alcohol
DA
DA
DA
DA DADA
DA
Reward Circuits
DADA DA
DA
DA
Reward Circuits
DA
DA
DA
DA DA
DA
Drug Abuser
Non-Drug
Abuser
10. Expect overvaluation of analgesics
Opioids, benzodiazepines, stimulants and
cannabinoids trick brain systems
Expect overvaluation of these medications
even in patients without true addiction
Plan to evaluate effectiveness of these
medications by objective (functional) criteria
11. Substance Use Disorder? Look again.
Pseudo – addiction
Pain relief seeking not drug addiction
May finish meds early
May double doctor or go to emerg
Often iatrogenic:
Not dosing on the ½ life of med
Inadequate amount
Unrealistic expectations for pain relief
Should disappear with dose stabilization +
education. If not …perhaps addiction is occurring
12.
13. Depression and Chronic Pain
Serotonin (5-HT) and
norepinephrine (NE)…
Key mediators of mood
Part of the body’s
endogenous analgesic system
Opiates
– Cortex
Lateral Hypothal.
Thalamus
Amygdala
Medulla
NE
5-HT
– GLU
Substance P +
GABA
Interneuron –
Nociceptor
A
A, c
14. Adverse Childhood Experiences
(ACE) – within first 18 years of life
≥ 4 ACE categories = 4-12x risk of SUD
1. Emotional abuse
2. Physical abuse
3. Sexual abuse
4. Emotional neglect
5. Physical neglect
6. Mother treated violently
7. Household substance abuse
8. Household mental illness/suicide attempt
9. Parental separation or divorce
10. Incarcerated household member
16. Chronic Substance Use and also Chronic
Pain Produce a Different Nervous System
Long term brain changes:
Metabolic activity
Neurotransmitter release
Gene expression
Receptor sensitivity & availability
Cue responsiveness
Behavioral and cognitive changes
17. Goals of Treatment (Pain & SUDs)
Reduction of suffering
Correction of sleep disturbance
Reduction of anxiety and depression
Restoration of function
Elimination of unnecessary dependence
on medications
18. The 5As – Functional Assessment
1. Activities of daily living
Work, self care, mobility, leisure, sport, sleep
2. Analgesia
3. Adverse effects
4. Affect
5. Aberrant drug-related behaviors
+ Accurate medication log
+ Ask relatives/friends/coworkers
19. Sleep/Mood Issues with SUD/Pain
Education, sleep hygiene, exercise, caffeine elim.
Cognitive therapy, social support
Meds for sleep cycle regulation +/- pain
Benzodiazepines contraindicated
Tricyclic or tetracyclic antidepressant
Antipsychotics
For pain +/- mood
SNRIs (duloxetine, venlafaxine)
For primary mood issues
SNRIs or SSRIs (citalopram, paroxetine, sertraline)
20. Addiction to Pain Medications
Those at highest risk:
Active SUD
Past Hx of SUD
Family Hx of SUD
Active psychiatric illness
Early childhood trauma history
Youth
Past minor injuries requiring prolonged opioid Rx
Tight contracts, follow-up, and collateral
21. Opioids - tips
Studies show analgesia up to 20-30%
Fantasy of perfect analgesic control
Watchful dose = 200 mg
Morphine Equivalent Daily Dose (MEDD)
Reduce the affective component of pain
“I still feel the pain but I don’t care”
Noradrenalin suppression in LC, calming
Withdrawal can be very painful & drive use
22. Canadian Opioid Guidelines (Furlan 2010)
Best Practice for Opioid Therapy
Complete history, physical, differential Dx
Risk assessment SUD, psychiatric issues
Medication review + urine drug screen
Appropriate trial of non-opioid alternatives
Pre/post-opioid pain and function questions
Treatment agreement: 1 MD, visits, scripts
Taper off benzodiazepines first
Sufficient trial of opioid, establish efficacy
Use Opioid Manager + PharmaNet each visit
23. Canadian Opioid Guidelines
Patients at High Risk for SUD
Prescribe only for well-defined somatic or
neuropathic pain conditions
Relatively contraindicated in headache and fibromyalgia
Start with lower doses and titrate in small
dose increments
Monitor closely for signs of aberrant drug
related behaviors
24. Patient in Recovery and Acute Pain
53 year old male teacher, 10 years sober from
alcohol dependence, with appendicitis
He expresses fear of relapse if given opioids post op
Can try non-opioid options first (med and psych)
If no opioid – you can revisit if decompensating
If opioid tried – short scripts, discuss warning signs
for relapse, collateral info, firm sunset clause
Increase supports – family, friends, 12 step, etc.
25. Canadian Opioid Guidelines
For Patients with Opioid Dependence
THREE options only
Methadone or buprenorphine treatment
Structured opioid therapy – e.g. once daily
morphine – daily witnessed ingestion until stable
Abstinence based treatment
N.B. Relapse can be triggered by…
Stress
Pain
Exposure to any addictive substance
26. Patients on Methadone or with SUD
Mild to moderate acute/chronic pain treatment
High dose NSAIDs and acetaminophen
TCAs, SNRIs, neuromodulators (beware of street
value of gabapentin)
Topicals, ice/heat, myofacial release techniques
stress reduction/mindfulness/breathing techniques
Counselling, AA, NA, social engagement
Exercise
Sleep hygiene
27. Patients on Opioid Maintenance
Severe Acute/Chronic Pain Treatment
Consider all of the items on previous slide
Split methadone q6-8h and increase as needed
And/or …Additional opioid trial:
Oxycodone, hydromorphone, fentanyl, witnessed inj.
Sunset clause if acute pain
Explore perceived disability and meaning
In hospital get pain service or anesthesia to see
Procedures: nerve root blocks, epidurals, ketamine
infusions, sympathetic blocks, regional blocks
28. Precautions if Any Active SUD
Bubble pack medications
Random call backs for pill counts
RANDOM urine drug screens
Look for illicit substances, ensure taking prescription
Include ethyl glucoronide (ETG) – 3-5d past alcohol use
Put onto once daily formulations with daily
witnessed ingestion at the pharmacy (no carries)
Taper off opioids if drinking alcohol or on benzos
29. Random UDT Indicated for Those Treated
with Opioids - Katz 2003
21 % of patients receiving opioids with NO
aberrant behaviors had…
Positive urine drug screen for illicit drugs or for non-
prescribed controlled substances.
14 % of patients receiving opioids with
significant aberrant behaviors had:
• Negative urinary drug screen for the medication
prescribed.
30. 45 year old female cook presents with hand pain after
a first degree grease burn treated yesterday in emerg.
She drinks 3-4 glasses of wine/night at work, then
binges at home. You suggest…
1. Referral to a plastic surgeon
2. Acetaminophen, NSAID and PPI with referral
for an addiction assessment
3. Opioids can be given first line since severe
pain can trigger more drinking
4. Medical marijuana is a good choice since it is
unlikely to interfere with alcohol metabolism
31. 19 year old street entrenched youth shooting
heroin is hit by a car as a pedestrian and
sustains a femur fracture requiring
instrumentation. What would you suggest for
pain management over the next few months?
1. Gabapentin and acetaminophen
2. Oxycodone/acetaminophen prn with a clear
sunset clause after 3 months
3. High dose methadone maintenance,
naproxen, and housing referral
4. Venlafaxine and meloxicam
32. When to Suggest Opioid Taper?
Patient on opioids without significant
improvement in pain and function
Safety sensitive position
Spread of pain in the absence of disease
progression - allodynia and hyperalgesia
Active substance abuse/dependence where
harm reduction is either not a consideration
or not viable
Patient requests to come off
33. Essentials for Med Prescribing
Identify those at highest risk
Negotiate a clear behavioral contract
If a chemical reinforcer is tried
unsuccessfully – STOP
Focus on function
Early (sustainable) return to work
It is OK to refer on for assistance
34. We Feel Our Patients’ Pain
Mirror Neurons activate seeing others in pain
So no wonder we are uncomfortable!
We empathize, then we…
Try to stop their suffering – write a prescription
We protect ourselves (and push patient away)
Get angry and fire them
Cut them off emotionally
Give them a script to get them out of the office
35. Instead we need to become more comfortable
in acknowledging the suffering in ourselves
and others
And make sure our prescribing is not a
reaction to our own empathic suffering
36. Medications are a fantastic tool,
but if they are not working…
Review the diagnosis – Repeat Hx/Px
Tolerance, opioid induced hyperalgesia,
substance dependence or diversion?
Screen for depression, anxiety, and PTSD
Explore perception of disability & meaning
Consider somatoform disorders
Avoid iatrogenic pain and suffering
38. Recovery from Pain and Addiction
Patient responsibility (active self management)
Recovery is largely non-pharmacological
Essential to recognize and correct negative
cognitive distortions (leading to dysphoria)
Identify and practice recovery/happiness skills:
aerobic exercise, balance, altruism, social
interactions, accountability, spiritual growth,
meditation, nutrition, and fun
Essentials of Happiness
Recovery is unlikely in the intoxicated/impaired patient
41. References
Ballantyne J, Shin N. Efficacy of opioids for chronic pain: A review
of the evidence. Clin j Pain. 24 (6) July/Aug 2006
Furlan A. et al. Opioids for chronic non-cancer pain: A new Canadian
guideline. CMAJ early release May 3, 2010 www.cmaj.ca and
http://nationalpaincentre.mcmaster.ca/opioid/
And http://nationalpaincentre.mcmaster.ca/opioidmanager/
Drugs for pain. Treatment guidelines from The Medical Letter, vol. 8
(issue 92) April 2010
Chou R. et al. Opioid Treatment Guidelines. Journal of Pain, vol 10,
No 2 (February), 2009: pp 113-130, see www.sciencedirect.com
Nuckols et al. Opioid Prescribing: A Systematic Review and Critical
Appraisal of Guidelines for Chronic Pain. Annals of Internal Med.
Nov. 2013
42. References, continued
Katz, NP et al. Random UDT Indicated for Those Treated with Opioids J
Anesth Analg 2003 October; 97 (4): 1097-1102
Gabapentin for pain: New evidence from hidden data. Therapeutics
Initiative, 75, July-Dec. 2009
Malinoff, H. Medical Management of Patients Withdrawn from High
Dose Opioid Therapy for Chronic Pain. Paper presentation, American
Society of Addiction Medciine Med-Sci Conference, April 19-22, 2012,
Atlanta Georgia
Butler D and Moseley L. Explain Pain. Noigroup Publications, Adelaide,
Australia (2003)
Ziegler P. Safe Treatment of Pain in the Patient With a Substance Use
Disorder. Psychiatric Times (CMP Medica), 24(1), 2007
Saarela et al., Compassionate Brain: Humans detect intensity of pain from
another’s face. Cerebral Cortex. 2007:17: 230-7.
43. References, continued
Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for
acute and chronic pain in adults. Cochrane Database of Systematic
Reviews 2009, Issue 3. Art. No.: CD007076. DOI:
10.1002/14651858.CD007076.pub2
Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T.
Antipsychotics for acute and chronic pain in adults. Cochrane Database of
Systematic Reviews 2013, Issue 9. Art. No.: CD004844. DOI:
10.1002/14651858.CD004844.pub3
Eccleston C, Palermo TM, Williams AC de C, Lewandowski A, Morley
S, Fisher E, Law E. Psychological therapies for the management of
chronic and recurrent pain in children and adolescents. Cochrane
Database of Systematic Reviews 2013, Issue 8. Art. No.: CD003968.
DOI: 10.1002/14651858.CD003968.pub3
Martin-Sanchez et al. Systemic Review and Meta-analysis of Cannabis
Treatment for Chronic Pain. Pain Medicine Vol 10 (8) 2009: 1353-1368
44. References, continued
Duehmke RM, Hollingshead J, Cornblath DR. Tramadol for neuropathic
pain. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.:
CD003726. DOI: 10.1002/14651858.CD003726.pub3
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane
Database of Systematic Reviews 2007, Issue 4. Art. No.: CD005454.
DOI: 10.1002/14651858.CD005454.pub2
Wiffen PJ, Derry S, Moore R, Aldington D, Cole P, Rice AS C, Lunn
MPT, Hamunen K, Haanpaa M, Kalso EA. Antiepileptic drugs for
neuropathic pain and fibromyalgia - an overview of Cochrane reviews.
Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.:
CD010567. DOI: 10.1002/14651858.CD010567.pub2
National Institute on Drug Abuse (NIDA) Teaching Packet No. 5:
“Bringing the Power of Science to Bear on Drug Abuse and Addiction”
http://www.nida.nih.gov/pubs/teaching/Teaching5/Teaching4.html
45. References, continued
Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetine for treating painful
neuropathy or chronic pain. Cochrane Database of Systematic Reviews
2009, Issue 4. Art. No.: CD007115. DOI:
10.1002/14651858.CD007115.pub2
Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for
neuropathic pain. Cochrane Database of Systematic Reviews 2013, Issue
11. Art. No.: CD007963. DOI: 10.1002/14651858.CD007963.pub2
Hadley G, Derry S, Moore R, Wiffen PJ. Transdermal fentanyl for cancer
pain. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.:
CD010270. DOI: 10.1002/14651858.CD010270.pub2
Quigley C. Hydromorphone for acute and chronic pain. Cochrane
Database of Systematic Reviews 2013, Issue 9. Art. No.: CD003447.
DOI: 10.1002/14651858.CD003447
Rieb, L. Spreading pain with neuropathic features may be induced by
opioid medications. This Changed My Practice. UBC CPD, Sept. 13,
2011 http://thischangedmypractice.com/
46. References, continued
Chaparro L, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk
DC. Opioids compared to placebo or other treatments for chronic low-
back pain. Cochrane Database of Systematic Reviews 2013, Issue 8. Art.
No.: CD004959. DOI: 10.1002/14651858.CD004959.pub4
McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain.
Cochrane Database of Systematic Reviews 2013, Issue 9. Art. No.:
CD006146. DOI: 10.1002/14651858.CD006146.pub2
Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C,
Schoelles KM. Long-term opioid management for chronic noncancer
pain. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.:
CD006605. DOI: 10.1002/14651858.CD006605.pub2
Derry P, Derry S, Moore RA, McQuay HJ. Single dose oral diclofenac for
acute postoperative pain in adults. Cochrane Database of Systematic
Reviews 2009, Issue 2. Art. No.: CD004768. DOI:
10.1002/14651858.CD004768.pub2